Gå til innholdet
Menu

PHARMAQ has received Marketing Authorizations (MA) for a Nodavirus vaccine for European sea bass in Spain, Italy, Croatia and Greece.

• ALPHA JECT micro 1 Noda, is the first and only commercially available vaccine against Viral Nervous Necrosis (VNN), in Europe.
• A micro dose emulsion for injection in sea bass allowing vaccination of smaller fish and showing high protection and duration of immunity for up to at least one year
• Viral Nervous Necrosis is the most important viral disease affecting sea bass in the Mediterranean

21st of February 2018, PHARMAQ, a business of Zoetis, has received Marketing Authorisations in Spain, Italy, Croatia and Greece for an injectable vaccine to help fish farmers combat Nodavirus in European sea bass.

Morten Nordstad, President of PHARMAQ, said that “ALPHA JECT micro 1 Noda has been developed in response to fish farmers’ needs in the Mediterranean to fight against the most common viral disease affecting farmed sea bass in the Mediterranean. PHARMAQ is committed to the continuous development and supply of innovative health solutions for fish farmers globally.”

A new innovative solution against Nodavirus infection in Sea Bass
Viral Nervous Necrosis caused by Nodavirus, is one of the most important diseases in farming of sea bass in the Mediterranean Sea. VNN affects all production stages and causes a significant financial impact due to the high mortality rates and reduction of growth performance. ALPHA JECT micro 1 Noda has been available as an emergency vaccine* in some Mediterranean countries since 2014. The results from commercial scale use have so far been promising.

ALPHA JECT micro 1 Noda is the first of a new generation of PHARMAQ's micro dose (0.05 ml per fish) oil-based injectable vaccines to be introduced to the Mediterranean market. PHARMAQ’s micro dose technology offers significant benefits from a welfare perspective according to Roberto Guijarro, General Manager and veterinarian, at PHARMAQ Spain Aqua. “The micro dose allows vaccination of smaller fish and reduces the levels of local reactions. Also, the studies have shown a high protection and duration of immunity for up to at least one year has been documented in laboratory studies”.

For further information, please contact:
Morten Nordstad,
President PHARMAQ a business of Zoetis
Mobile: +47 907 52 853
Or 
Roberto Guijarro,
General Manager, PHARMAQ Spain Aqua
Mobile: + 34 606 114 291

About PHARMAQ

PHARMAQ is the global leader in vaccines and innovation for aquaculture and part of Zoetis, the world leader in animal health. The company provides environmentally sound, safe and efficacious health products to the global aquaculture industry through targeted research and the commitment of dedicated people. Production facilities, administration and research and development activities are based in Norway with subsidiaries in Chile, United Kingdom, China, Vietnam, Turkey, Spain, Panama and Singapore. PHARMAQ has approximately 220 employees. The company's products are marketed in Europe, North and South America, and Asia. For further information, visit the company's website at www.pharmaq.com

*For Greece it has been sold as an autogenous vaccine  and for Spain it has been an emergency license under the Spanish regulation artículo 29 del Real Decreto 1246/2008. For Cyprus it has been an emergency license.

Did you know...

WE MAKE AQUACULTURE PROGRESS

Newsfeed delivered by Meltwater News. PHARMAQ is not to be held liable for any of its content nor possible incorrect information given.

»
»
»
»
»
»
»
»
»
»

Norway

Head office
Production facility
PHARMAQ AS
Skogmo Industriområde
Industrivegen 50
7863 Overhalla, Norway
Tel:+47 74 28 08 00
Fax:+47 74 28 08 01

Oslo office
PHARMAQ AS
Harbitzalléen 2A, 0275 Oslo,
P.O.Box 267 Skøyen, N-0213 Oslo, Norway
Tel: +47 23 29 85 00
Fax: :+47 23 29 85 01
customer.service​@pharmaq.no

Chile

PHARMAQ AS Chile Ltda.
Bernardino # 1981, Piso 2, Oficina 202,
Parque Empresarial San Andrés,
Puerto Montt, Chile
Tel: +56 65 248 3091
customer.service​@pharmaq.no

 

United Kingdom

PHARMAQ Ltd.
Unit 15 Sandleheath Industrial Estate,
Fordingbridge,
Hampshire SP6 1PA,
United Kingdom
Tel: +44 1425 656081
Fax: +44-1425 657992
orders@pharmaq.no

Terms & Conditions of Purchase
Terms & Conditions of Sale
Tax strategy and Disclosure: Financial year ending 30 November 2017

Turkey

PHARMAQ Veteriner Ecza Deposu ve Su Ürünleri Tic.Ltd.Şti
KARACAOGLAN MAH. 6166 SK. 21 A BORNOVA/ IZMIR Turkiye
Tel: +90 232 422 23 10
Fax:+90 232 422 32 27
customer.service​@pharmaq.no

Vietnam

PHARMAQ VIETNAM Co. LTD.
8th Fl. , R. 8.5A, E Town Tower
364 Cong Hoa, W.13, D.Tan Binh
Ho Chi Minh City
Vietnam
Tel : +84 08 3812 2461
Fax : +84 08 3812 2712
customer.service​@pharmaq.no

Panama

PHARMAQ CA Panama Inc.
P.H. Albrook Commercial Park, piso 2,
Oficina 108 Ave. Bella Vista, Ancón
Panamá – Panamá
Phone: +507 3215363
Mob.: +507 6675 1109
customer.service​@pharmaq.no

Spain

PHARMAQ Spain Aqua
Avda de Europa 20B
Parque Empresarial La Moraleja
28108 Alcobendas, Spain
Tel: +34 91 419 19 35
customer.service​@pharmaq.no

Singapore

PHARMAQ part of Zoetis
108 Pasir Panjang Road
Singapore 118535, Singapore
Tel.: +65 6933 5800
customer.service​@pharmaq.no

PHARMAQ is the global leader in vaccines and innovation for aquaculture and part of Zoetis, the world leader in animal health. The company provides environmentally sound, safe and efficacious health products to the global aquaculture industry through targeted research and the commitment of dedicated people. Production facilities, administration and research and development activities are based in Norway with subsidiaries in Chile, United Kingdom, Vietnam, Turkey, Spain, Panama and Hong Kong. PHARMAQ has approximately 200 employees. The company's products are marketed in Europe, North and South America, and Asia. For further information, visit the company's website at www.pharmaq.comPrivacy Policy. Cookie Policy. Terms of Use.

Copyright © 2016 Zoetis LLC. All rights reserved.

Utviklet av Imaker as